Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).

Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M.

Mol Genet Metab. 2011 Nov;104(3):383-9. doi: 10.1016/j.ymgme.2011.07.007. Epub 2011 Jul 12.

2.

Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data.

Clément MC, Mahlaoui N, Mignot C, Le Bihan C, Rabetrano H, Hoang L, Neven B, Moshous D, Cavazzana M, Blanche S, Fischer A, Audrain M, Durand-Zaleski I.

J Allergy Clin Immunol. 2015 Jun;135(6):1589-93. doi: 10.1016/j.jaci.2015.02.004. Epub 2015 Apr 1.

PMID:
25840725
3.

Potential costs and benefits of newborn screening for severe combined immunodeficiency.

McGhee SA, Stiehm ER, McCabe ER.

J Pediatr. 2005 Nov;147(5):603-8.

PMID:
16291349
4.

Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.

Ding Y, Thompson JD, Kobrynski L, Ojodu J, Zarbalian G, Grosse SD.

J Pediatr. 2016 May;172:127-35. doi: 10.1016/j.jpeds.2016.01.029. Epub 2016 Feb 11.

5.

An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia.

Modell V, Knaus M, Modell F.

Immunol Res. 2014 Oct;60(1):145-52. doi: 10.1007/s12026-014-8485-4.

PMID:
24599744
6.

Newborn screening for severe combined immune deficiency (technical and political aspects).

Kobrynski L.

Curr Opin Allergy Clin Immunol. 2015 Dec;15(6):539-46. doi: 10.1097/ACI.0000000000000221. Review.

PMID:
26485096
7.

Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.

Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, Baker M, Ballow M, Bartoshesky LE, Bonilla FA, Brokopp C, Brooks E, Caggana M, Celestin J, Church JA, Comeau AM, Connelly JA, Cowan MJ, Cunningham-Rundles C, Dasu T, Dave N, De La Morena MT, Duffner U, Fong CT, Forbes L, Freedenberg D, Gelfand EW, Hale JE, Hanson IC, Hay BN, Hu D, Infante A, Johnson D, Kapoor N, Kay DM, Kohn DB, Lee R, Lehman H, Lin Z, Lorey F, Abdel-Mageed A, Manning A, McGhee S, Moore TB, Naides SJ, Notarangelo LD, Orange JS, Pai SY, Porteus M, Rodriguez R, Romberg N, Routes J, Ruehle M, Rubenstein A, Saavedra-Matiz CA, Scott G, Scott PM, Secord E, Seroogy C, Shearer WT, Siegel S, Silvers SK, Stiehm ER, Sugerman RW, Sullivan JL, Tanksley S, Tierce ML 4th, Verbsky J, Vogel B, Walker R, Walkovich K, Walter JE, Wasserman RL, Watson MS, Weinberg GA, Weiner LB, Wood H, Yates AB, Puck JM, Bonagura VR.

JAMA. 2014 Aug 20;312(7):729-38. doi: 10.1001/jama.2014.9132. Erratum in: JAMA. 2014 Nov 26;312(20):2169. Bonagura, Vincent R [Added].

8.

Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.

Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, Stanley CA.

Pediatrics. 2003 Nov;112(5):1005-15.

PMID:
14595039
9.

History and current status of newborn screening for severe combined immunodeficiency.

Kwan A, Puck JM.

Semin Perinatol. 2015 Apr;39(3):194-205. doi: 10.1053/j.semperi.2015.03.004. Epub 2015 Apr 30. Review.

10.

An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.

Thiboonboon K, Leelahavarong P, Wattanasirichaigoon D, Vatanavicharn N, Wasant P, Shotelersuk V, Pangkanon S, Kuptanon C, Chaisomchit S, Teerawattananon Y.

PLoS One. 2015 Aug 10;10(8):e0134782. doi: 10.1371/journal.pone.0134782. eCollection 2015.

11.

[Neonatal screening of severe combined immunodeficiencies].

Thomas C, Mirallié S, Pierres C, Dert C, Clément MC, Mahlaoui N, Durand-Zaleski I, Fischer A, Audrain M; DEPISTREC Group.

Arch Pediatr. 2015 Jun;22(6):646-52. doi: 10.1016/j.arcped.2015.03.001. Epub 2015 Apr 18. French.

PMID:
25896629
12.

Economic model of a birth cohort screening program for hepatitis C virus.

McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC.

Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.

PMID:
22135116
13.

Cost-effectiveness of expanded newborn screening in Texas.

Tiwana SK, Rascati KL, Park H.

Value Health. 2012 Jul-Aug;15(5):613-21. doi: 10.1016/j.jval.2012.02.007. Epub 2012 Jun 7.

14.

Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.

Hamers FF, Rumeau-Pichon C.

BMC Pediatr. 2012 Jun 8;12:60. doi: 10.1186/1471-2431-12-60.

15.

Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency.

Kubiak C, Jyonouchi S, Kuo C, Garcia-Lloret M, Dorsey MJ, Sleasman J, Zbrozek AS, Perez EE.

J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):697-702. doi: 10.1016/j.jaip.2014.05.013. Epub 2014 Aug 28.

PMID:
25439359
16.

Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years.

Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, Lewis DB, McGhee SA, Moore TB, Stiehm ER, Porteus M, Aznar CP, Currier R, Lorey F, Puck JM.

J Allergy Clin Immunol. 2013 Jul;132(1):140-50. doi: 10.1016/j.jaci.2013.04.024.

17.

The Wisconsin approach to newborn screening for severe combined immunodeficiency.

Verbsky J, Thakar M, Routes J.

J Allergy Clin Immunol. 2012 Mar;129(3):622-7. doi: 10.1016/j.jaci.2011.12.004. Epub 2012 Jan 11.

PMID:
22244594
18.

Two-tiered universal newborn screening strategy for severe combined immunodeficiency.

McGhee SA, Stiehm ER, Cowan M, Krogstad P, McCabe ER.

Mol Genet Metab. 2005 Dec;86(4):427-30. Epub 2005 Nov 2.

PMID:
16260163

Supplemental Content

Support Center